Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism.

By G. Rice, Daniel A. Thomas, P. Grant, A. Turner, N. Hooper. Biochemical Journal, 2004

597 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/838e7fdf217876d0060e3f5b5866e8bdb9ff5796

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Grant
2. J. Zhong
3. Vaibhav B. Patel
4. G. Oudit

In Endocrinology, Diabetes and Metabolism

1. M. Grant
2. J. Zhong
3. Vaibhav B. Patel
4. G. Oudit

In Molecular Biology

1. M. Grant
2. J. Zhong
3. Vaibhav B. Patel
4. G. Oudit

Citations in the corpus

• Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (2020, background): “9, 13 Despite these uncertainties, some have recommended cessation of treatment with ACE inhibitors and ARBs in patients with Covid-19.”
• Role of the ACE2/Angiotensin 1–7 axis of the Renin-Angiotensin System in Heart Failure (2016, background): “lytic efficiency is 400-fold higher with Ang II as a substrate than with Ang I.(38,42) To further unravel the biological role and”
• Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System (2020, background): “28, 125 Due to the short half-life of endogenous apelin peptides in the plasma, synthetic apelin peptide analogs resistant to ACE2 degradation and retaining their binding capability to endogenous apelin receptors elicit protection in the cardiovascular system are being explored as potential new ther”